Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Tasquinimod Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects By Inhibiting c-Myc Expression in Vitro and In Vivo

Rong Fan, Hatice Satilmis, Niels Vandewalle, Elke De Bruyne, Eline Menu, Andrew D Chantry, Holly Evans, Marie Törngren, Helena Eriksson, Karine Breckpot, Ken Maes, Karin Vanderkerken, Kim De Veirman

Blood (2021) 138 (Supplement 1): 1594.

https://doi.org/10.1182/blood-2021-147744

Published: 2021

Journal Articles

The Exosomal Transfer of Acid Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma

Inge Oudaert, MSc, Sylvia Faict, MSc, Ludovic D'Auria, PhD, Jonas Dehairs, PhD, Ken Maes, Philip Vlummens, MD, Lotte Jacobs, BSc, Kim De Veirman, Elke De Bruyne, PhD, Karel Fostier, MD, Isabelle Vande Broek, MD PhD, Rik Schots, Karin Vanderkerken, PhD, Johannes V. Swinnen, PhD, Eline Menu, PhD

Blood (2019) 134 (Supplement_1): 3058.

https://doi.org/10.1182/blood-2019-122857

Published: 2019

Journal Articles

Receptor Tyrosine Kinase AXL: A Potential Strategy to Counter Immune Suppression and Dormancy in Multiple Myeloma

Kim De Veirman, Siyang Yan, Ken Maes, Nathan De Beule, MD, Sylvia Faict, MSc, Elke De Bruyne, PhD, Eline Menu, PhD, Karin Vanderkerken, PhD

Blood (2019) 134 (Supplement_1): 4335.

https://doi.org/10.1182/blood-2019-126834

Published: 2019

Journal Articles

MCL1 Inhibitors in Multiple Myeloma

Karin Vanderkerken, PhD, Kim De Veirman, Ken Maes, Eline Menu, PhD, Elke De Bruyne, PhD

Blood (2019) 134 (Supplement_1): SCI-12.

https://doi.org/10.1182/blood-2019-121104

Published: 2019

Journal Articles

Exosomes Play a Key Role in Multiple Myeloma Bone Disease and Tumor Development

Sylvia Faict, MD, Josephine Muller, PhD, Kim De Veirman, PhD, Ken Maes, Elke De Bruyne, PhD, Rik Schots, Jo Caers, MD PhD, Karin Vanderkerken, PhD, Eline Menu, PhD

Blood (2018) 132 (Supplement 1): 4484.

https://doi.org/10.1182/blood-2018-99-112428

Published: 2018

Journal Articles

Histone Methyltransferases G9a and GLP; Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma Treatment

Eva De Smedt, Julie Devin, Hui Liu, Anke Maes, Ken Maes, Kim De Veirman, Eline Menu, PhD, Karin Vanderkerken, PhD, Jerome Moreaux, PhD, Elke De Bruyne, PhD

Blood (2017) 130 (Supplement 1): 4356.

https://doi.org/10.1182/blood.V130.Suppl_1.4356.4356

Published: 2017

Journal Articles

The Anaphase Promoting Complex/Cyclosome: A New Promising Target in Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma

Anke Maes, Eva De Smedt, Kim De Veirman, Ken Maes, Eline Menu, PhD, Els Van Valckenborgh, PhD, Karin Vanderkerken, PhD, Elke De Bruyne, PhD

Blood (2017) 130 (Supplement 1): 2757.

https://doi.org/10.1182/blood.V130.Suppl_1.2757.2757

Published: 2017

Journal Articles

Targeting S100A9 Interactions in the Multiple Myeloma Bone Marrow Environment Reduces Angiogenesis and Tumor Growth

Kim De Veirman, PhD, Els Van Valckenborgh, PhD, Nathan De Beule, MD, Hendrik De Raeve, Ken Maes, PhD, Elke De Bruyne, PhD, Eline Menu, PhD, Karin Vanderkerken, PhD

Blood (2016) 128 (22): 3248.

https://doi.org/10.1182/blood.V128.22.3248.3248

Published: 2016

Journal Articles

RAS Association Domain Family Member 4 (RASSF4): A New Potent Tumor Suppressor in Multiple Myeloma

Eva De Smedt, Ken Maes, PhD, Stefan Verhulst, Hui Lui, Alboukadel Kassambara, PhD, Anke Maes, Dirk Hose, MD, Karine Breckpot, Jerome Moreaux, PhD, Elke De Bruyne, PhD

Blood (2016) 128 (22): 2057.

https://doi.org/10.1182/blood.V128.22.2057.2057

Published: 2016

Journal Articles

The Crosstalk Between Leptin Receptor Activation and iNKT Mediated Anti-Tumor Immunity in Multiple Myeloma

Mérédis Favreau, PhDstudent, Eline Menu, PhD, Karin Vanderkerken, PhD, Sylvia Faict, MD, Ken Maes, PhD, Els Van Valckenborgh, PhD, Elke De Bruyne, PhD, Srinath Govindarajan, PhDstudent, Michael Drennan, PhD, Xavier Leleu, Lennart Zabeau, PhD, Jan Tavernier, PhD, Koen Venken, PhD, Dirk Elewaut, MD PhD

Blood (2016) 128 (22): 2075.

https://doi.org/10.1182/blood.V128.22.2075.2075

Published: 2016

Journal Articles

Targeting the Anaphase Promoting Complex/Cyclosome (APC/C) in Multiple Myeloma

Susanne Lub, Anke Maes, Ken Maes, Kim De Veirman, Xavier Leleu, MD PhD, Eline Menu, PhD, Elke De Bruyne, PhD, Karin Vanderkerken, PhD, Els Van Valckenborgh, PhD

Blood (2014) 124 (21): 2097.

https://doi.org/10.1182/blood.V124.21.2097.2097

Published: 2014

Journal Articles

The in vivo Transcriptional Response Towards Epigenetic Modulating Agents in Multiple Myeloma

Ken Maes, Eva De Smedt, Kassambara Alboukadel, PhD, Dirk Hose, MD PhD, Anja Seckinger, MD PhD, Els Van Valckenborgh, PhD, Eline Menu, PhD, Bernard Klein, MD PhD, Karin Vanderkerken, PhD, Jerome Moreaux, PhD, Elke De Bruyne, PhD

Blood (2014) 124 (21): 3375.

https://doi.org/10.1182/blood.V124.21.3375.3375

Published: 2014

Journal Articles

The DNA Methyltransferase Inhibitor Decitabine Induces DNA Damage, Cell Cycle Arrest and Apoptosis in Multiple Myeloma

Ken Maes, Miguel Lemaire, Jordan Gauthier, Hendrik De Raeve, Eline Menu, PhD, Els Van Valckenborgh, PhD, Helena Jernberg Wiklund, PhD, Karin Vanderkerken, PhD, Elke De Bruyne, PhD

Blood (2012) 120 (21): 1833.

https://doi.org/10.1182/blood.V120.21.1833.1833

Published: 2012

Journal Articles

Combination of the IGF-1 Receptor Inhibitor Picropodophylin and the BH3 Mimetic ABT-737 Has Synergistic Anti-Myeloma Activity

Liesbeth Bieghs, Ken Maes, Els Van Valckenborgh, PhD, Eline Menu, PhD, Hans Erik Johnsen, Mette Nyegaard, PhD, Helena Jernberg Wiklund, PhD, Karin Vanderkerken, PhD, Elke De Bruyne, PhD

Blood (2012) 120 (21): 4010.

https://doi.org/10.1182/blood.V120.21.4010.4010

Published: 2012

Journal Articles

In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2

Ken Maes, Elizabeta Nemeth, G. David Roodman, Alissa Huston, Flavia Esteve, Cesar Freytes, Natalie Callander, Eirini Katodritou, Lisa Tussing-Humphreys, Seth Rivera, Karin Vanderkerken, Alan Lichtenstein, Tomas Ganz

Blood (2010) 116 (18): 3635–3644.

https://doi.org/10.1182/blood-2010-03-274571

Published: 2010

Includes: Supplemental data

Journal Articles

Characterization of Hepcidin-Inducing Cytokines in Multiple Myeloma.

Ken Maes, Alissa Huston, MD, David Roodman, MD, PhD, Seth Rivera, MD, PhD, Elizabeta Nemeth, PhD, Alan Lichtenstein, MD, Karin Vanderkerken, PhD, Tomas Ganz, MD, PhD

Blood (2009) 114 (22): 2001.

https://doi.org/10.1182/blood.V114.22.2001.2001

Published: 2009

NARROW

Tasquinimod Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects By Inhibiting c-Myc Expression in Vitro and In Vivo

The Exosomal Transfer of Acid Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma

Receptor Tyrosine Kinase AXL: A Potential Strategy to Counter Immune Suppression and Dormancy in Multiple Myeloma

MCL1 Inhibitors in Multiple Myeloma

Exosomes Play a Key Role in Multiple Myeloma Bone Disease and Tumor Development

Histone Methyltransferases G9a and GLP; Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma Treatment

The Anaphase Promoting Complex/Cyclosome: A New Promising Target in Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma

Targeting S100A9 Interactions in the Multiple Myeloma Bone Marrow Environment Reduces Angiogenesis and Tumor Growth

RAS Association Domain Family Member 4 (RASSF4): A New Potent Tumor Suppressor in Multiple Myeloma

The Crosstalk Between Leptin Receptor Activation and iNKT Mediated Anti-Tumor Immunity in Multiple Myeloma

Targeting the Anaphase Promoting Complex/Cyclosome (APC/C) in Multiple Myeloma

The in vivo Transcriptional Response Towards Epigenetic Modulating Agents in Multiple Myeloma

The DNA Methyltransferase Inhibitor Decitabine Induces DNA Damage, Cell Cycle Arrest and Apoptosis in Multiple Myeloma

Combination of the IGF-1 Receptor Inhibitor Picropodophylin and the BH3 Mimetic ABT-737 Has Synergistic Anti-Myeloma Activity

In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2

Characterization of Hepcidin-Inducing Cytokines in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only